Partner, Corporate Development
Jeremy joined Flagship in 2015 and develops strategic plans for VentureLabs® portfolio companies, works with corporate partners, and creates innovative approaches that will lead to the firm’s next breakthrough startups. Prior to joining Flagship, Jeremy was one of the original scientists at Alexion, where he played an integral role in the engineering and development of Alexion's antibody therapeutics and was one of the original inventors of the drug Soliris. He moved from research to business development, leveraging much of his drug development experience into the review of opportunities for ultra-orphan diseases. Jeremy has led or managed many of the recent deals for Alexion, worth more than $5 billion in deal value. These included the acquisitions of Enobia Pharma, Taligen Therapeutics and Orphatec as well as the partnership with Moderna Therapeutics. Along with driving business development for Alexion, he served in a key strategic role as Alexion transitioned from a development firm to a commercial stage company. Prior to 1992, Jeremy was an Instructor of Medicine at Harvard Medical School and a postdoctoral research fellow in the Cardiovascular Division of the Department of Medicine at the Brigham and Women’s Hospital. He received his Ph.D. from Louisiana State University Medical Center in New Orleans and his B.A. from Colby College. He is a member of the Licensing Executives Society and Biotechnology Industry Organization. Jeremy has also served as a member of the scientific advisory board to Arradial Inc. and currently serves as a Director of the Greater New Haven Chapter of the Juvenile Diabetes Research Foundation.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,